Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice

Arthritis and Rheumatology

Volumn 67, Issue 2, 2015, Pages 517-526

  Taniguchi, Takashi ^a   Asano, Yoshihide ^a   Akamata, Kaname ^a   Noda, Shinji ^a   Takahashi, Takehiro ^a   Ichimura, Yohei ^a   Toyama, Tetsuo ^a   Trojanowska, Maria ^b   Sato, Shinichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CD51 ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE; INTEGRIN ALPHA V BETA 3; INTEGRIN ALPHA V BETA 5; INTERLEUKIN 13; INTERLEUKIN 4; MESSENGER RNA; TRANSCRIPTION FACTOR FLI 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; CYTOKINE; FLI1 PROTEIN, MOUSE; INTEGRIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL INFILTRATION; CELL TRANSFORMATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENDOTHELIAL MESENCHYMAL TRANSITION; ENDOTHELIUM CELL; FEMALE; FIBROBLAST; GENE ACTIVATION; HAPLOINSUFFICIENCY; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MAST CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; TH17 CELL; TH2 CELL; UPREGULATION; WILD TYPE; ANIMAL; C57BL MOUSE; CELL MOTION; CHEMICALLY INDUCED; DEFICIENCY; DISEASE MODEL; EPITHELIAL MESENCHYMAL TRANSITION; FIBROSIS; GENETICS; IMMUNE SYSTEM; METABOLISM; MUTANT MOUSE STRAIN; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SKIN; VASCULAR ENDOTHELIUM;

ANIMALS; BLEOMYCIN; CELL MOVEMENT; CYTOKINES; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FIBROSIS; HAPLOINSUFFICIENCY; IMMUNE SYSTEM; INTEGRINS; MACROPHAGES; MAST CELLS; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; PROTO-ONCOGENE PROTEIN C-FLI-1; SCLERODERMA, SYSTEMIC; SKIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84922765338     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38948     Document Type: Article

References (48)

1. Asano Y,. Future treatments in systemic sclerosis. J Dermatol 2010; 37: 54-70.
2. Asano Y, Sato S,. Animal models of scleroderma: current state and recent development. Curr Rheumatol Rep 2013; 15: 382.
3. Wang Y, Fan PS, Kahaleh B,. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006; 54: 2271-9.
4. Asano Y, Czuwara J, Trojanowska M,. Transforming growth factor-β regulates DNA binding activity of transcription factor Fli1 by p300/CREB-binding protein-associated factor-dependent acetylation. J Biol Chem 2007; 282: 34672-83.
5. Chrobak I, Lenna S, Stawski L, Trojanowska M,. Interferon-γ promotes vascular remodeling in human microvascular endothelial cells by upregulating endothelin (ET)-1 and transforming growth factor (TGF) β2. J Cell Physiol 2013; 228: 1774-83.
6. Asano Y, Trojanowska M,. Phosphorylation of Fli1 at threonine 312 by protein kinase C δ promotes its interaction with p300/CREB-binding protein-associated factor and subsequent acetylation in response to transforming growth factor β. Mol Cell Biol 2009; 29: 1882-94.
7. Kubo M, Czuwara-Ladykowska J, Moussa O, Markiewicz M, Smith E, Silver RM, et al. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol 2003; 163: 571-81.
8. Asano Y, Markiewicz M, Kubo M, Szalai G, Watson DK, Trojanowska M,. Transcription factor Fli1 regulates collagen fibrillogenesis in mouse skin. Mol Cell Biol 2009; 29: 425-34.
9. Czuwara-Ladykowska J, Shirasaki F, Jackers P, Watson DK, Trojanowska M,. Fli-1 inhibits collagen type I production in dermal fibroblasts via an Sp1-dependent pathway. J Biol Chem 2001; 276: 20839-48.
10. Nakerakanti SS, Kapanadze B, Yamasaki M, Markiewicz M, Trojanowska M,. Fli1 and Ets1 have distinct roles in connective tissue growth factor/CCN2 gene regulation and induction of the profibrotic gene program. J Biol Chem 2006; 281: 25259-69.
11. Noda S, Asano Y, Akamata K, Aozasa N, Taniguchi T, Takahashi T, et al. A possible contribution of altered cathepsin B expression to the development of skin sclerosis and vasculopathy in systemic sclerosis. PLoS One 2012; 7: e32272.
12. Noda S, Asano Y, Takahashi T, Akamata K, Aozasa N, Taniguchi T, et al. Decreased cathepsin V expression due to Fli1 deficiency contributes to the development of dermal fibrosis and proliferative vasculopathy in systemic sclerosis. Rheumatology (Oxford) 2013; 52: 790-9.
13. 2A receptors promote collagen production by a Fli1- and CTGF-mediated mechanism. Arthritis Res Ther 2013; 15: R58.
14. Bujor AM, Haines P, Padilla C, Christmann RB, Junie M, Sampaio-Barros PD, et al. Ciprofloxacin has antifibrotic effects in scleroderma fibroblasts via downregulation of Dnmt1 and upregulation of Fli1. Int J Mol Med 2012; 30: 1473-80.
15. Nakerakanti SS, Bujor AM, Trojanowska M,. CCN2 is required for the TGF-β induced activation of Smad1-Erk1/2 signaling network. PLoS One 2011; 6: e21911.
16. Asano Y, Stawski L, Hant F, Highland K, Silver R, Szalai G, et al. Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol 2010; 176: 1983-98.
17. Spyropoulos DD, Pharr PN, Lavenburg KR, Jackers P, Papas TS, Ogawa M, et al. Hemorrhage, impaired hematopoiesis, and lethality in mouse embryos carrying a targeted disruption of the Fli1 transcription factor. Mol Cell Biol 2000; 20: 5643-52.
18. Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, et al. Animal model of sclerotic skin. I. Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999; 112: 456-62.
19. Yoshizaki A, Iwata Y, Komura K, Ogawa F, Hara T, Muroi E, et al. CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol 2008; 172: 1650-63.
20. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K,. Impaired Smad7-Smurf-mediated negative regulation of TGF-β signaling in scleroderma fibroblasts. J Clin Invest 2004; 113: 253-64.
21. Zeini M, Traves PG, Lopez-Fontal R, Pantoja C, Matheu A, Serrano M, et al. Specific contribution of p19(ARF) to nitric oxide-dependent apoptosis. J Immunol 2006; 177: 3327-36.
22. Asano Y, Ihn H, Yamane K, Jinnin M, Tamaki K,. Increased expression of integrin αVβ5 induces the myofibroblastic differentiation of dermal fibroblasts. Am J Pathol 2006; 168: 499-510.
23. Miller EJ, Rhodes RK,. Preparation and characterization of the different types of collagen. Methods Enzymol 1982; 82 Pt A: 33-64.
24. Markiewicz M, Asano Y, Znoyko S, Gong Y, Watson DK, Trojanowska M,. Distinct effects of gonadectomy in male and female mice on collagen fibrillogenesis in the skin. J Dermatol Sci 2007; 47: 217-26.
25. Yamamoto T, Takahashi Y, Takagawa S, Katayama I, Nishioka K,. Animal model of sclerotic skin. II. Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W/Wv mice. J Rheumatol 1999; 26: 2628-34.
26. Yamamoto T, Kuroda M, Nishioka K,. Animal model of sclerotic skin. III. Histopathological comparison of bleomycin-induced scleroderma in various mice strains. Arch Dermatol Res 2000; 292: 535-41.
27. Takagawa S, Lakos G, Mori Y, Yamamoto T, Nishioka K, Varga J,. Sustained activation of fibroblast transforming growth factor-β/Smad signaling in a murine model of scleroderma. J Invest Dermatol 2003; 121: 41-50.
28. Mori T, Kawara S, Shinozaki M, Hayashi N, Kakinuma T, Igarashi A, et al. Role and interaction of connective tissue growth factor with transforming growth factor-β in persistent fibrosis: a mouse fibrosis model. J Cell Physiol 1999; 181: 153-9.
29. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K,. Increased expression levels of integrin αVβ5 on scleroderma fibroblasts. Am J Pathol 2004; 164: 1275-92.
30. Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K,. Increased expression of integrin αVβ3 contributes to the establishment of autocrine TGF-β signaling in scleroderma fibroblasts. J Immunol 2005; 175: 7708-18.
31. Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K,. Involvement of αVβ5 integrin-mediated activation of latent transforming growth factor β1 in autocrine transforming growth factor β signaling in systemic sclerosis fibroblasts. Arthritis Rheum 2005; 52: 2897-905.
32. Abe M, Harpel JG, Metz CN, Nunes I, Loskutoff DJ, Rifkin DB,. An assay for transforming growth factor-β using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem 1994; 216: 276-84.
33. Kizu A, Medici D, Kalluri R,. Endothelial-mesenchymal transition as a novel mechanism for generating myofibroblasts during diabetic nephropathy. Am J Pathol 2009; 175: 1371-3.
34. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007; 13: 952-61.
35. Li J, Qu X, Bertram JF,. Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice. Am J Pathol 2009; 175: 1380-8.
36. Hashimoto N, Phan SH, Imaizumi K, Matsuo M, Nakashima H, Kawabe T, et al. Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2010; 43: 161-72.
37. Yoshizaki A, Yanaba K, Iwata Y, Komura K, Ogawa A, Akiyama Y, et al. Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model. J Immunol 2010; 185: 2502-15.
38. Hussein MR, Hassan HI, Hofny ER, Elkholy M, Fatehy NA, Abd Elmoniem AE, et al. Alterations of mononuclear inflammatory cells, CD4/CD8+ T cells, interleukin 1β, and tumour necrosis factor α in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis. J Clin Pathol 2005; 58: 178-84.
39. Higashi-Kuwata N, Jinnin M, Makino T, Fukushima S, Inoue Y, Muchemwa FC, et al. Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther 2010; 12: R128.
40. Ploeger DT, Hosper NA, Schipper M, Koerts JA, de Rond S, Bank RA,. Cell plasticity in wound healing: paracrine factors of M1/M2 polarized macrophages influence the phenotypical state of dermal fibroblasts. Cell Commun Signal 2013; 11: 29.
41. Han Y, Ma FY, Tesch GH, Manthey CL, Nikolic-Paterson DJ,. Role of macrophages in the fibrotic phase of rat crescentic glomerulonephritis. Am J Physiol Renal Physiol 2013; 304: F1043-53.
42. Wang J, Jiang ZP, Su N, Fan JJ, Ruan YP, Peng WX, et al. The role of peritoneal alternatively activated macrophages in the process of peritoneal fibrosis related to peritoneal dialysis. Int J Mol Sci 2013; 14: 10369-82.
43. Hamilton RF, Parsley E, Holian A,. Alveolar macrophages from systemic sclerosis patients: evidence for IL-4-mediated phenotype changes. Am J Physiol Lung Cell Mol Physiol 2004; 286: L1202-9.
44. Mathai SK, Gulati M, Peng X, Russell TR, Shaw AC, Rubinowitz AN, et al. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Lab Invest 2010; 90: 812-23.
45. Liu S, Shi-wen X, Abraham DJ, Leask A,. CCN2 is required for bleomycin-induced skin fibrosis in mice. Arthritis Rheum 2011; 63: 239-46.
46. Liu S, Parapuram SK, Leask A,. Fibrosis caused by loss of PTEN expression in mouse fibroblasts is crucially dependent on CCN2. Arthritis Rheum 2013; 65: 2940-4.
47. Henderson NC, Arnold TD, Katamura Y, Giacomini MM, Rodriguez JD, McCarty JH, et al. Targeting of αV integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med 2013; 19: 1617-24.
48. Hugle T, Hogan V, White KE, van Laar JM,. Mast cells are a source of transforming growth factor β in systemic sclerosis. Arthritis Rheum 2011; 63: 795-9.